Report of the Second European Expert Meeting on Rotavirus Vaccination

Report of the Second European Expert Meeting on Rotavirus Vaccination

Dr. Umesh Parashar (Centers for Disease Control and Prevention [CDC], USA) presented the projected impact of RV vaccination on childhood mortality, using a demand forecast model to predict adoption of RV vaccination in the lowest-income countries (eligible for GAVI Alliance funding). Belgium Nov 200...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2012-03, Vol.30 (13), p.2237-2244
Hauptverfasser: Giaquinto, Carlo, Jackson, Amy E.M, Vesikari, Timo
Format: Artikel
Sprache:eng
Schlagworte:
Age
Allergy and Immunology
Americas
Child, Preschool
Children & youth
Colleges & universities
Cost-Benefit Analysis
Europe
Humans
Immunity, Herd
Immunization
Israel
Meeting
Meetings
Rotarix
RotaTeq
Rotavirus
Rotavirus - immunology
Rotavirus Infections - epidemiology
Rotavirus Infections - immunology
Rotavirus Infections - prevention & control
Rotavirus Infections - virology
Rotavirus Vaccines - administration & dosage
Rotavirus Vaccines - adverse effects
Rotavirus Vaccines - economics
Treatment Outcome
UMV
Vaccination - statistics & numerical data
Vaccine
Vaccines
Viruses
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Dr. Umesh Parashar (Centers for Disease Control and Prevention [CDC], USA) presented the projected impact of RV vaccination on childhood mortality, using a demand forecast model to predict adoption of RV vaccination in the lowest-income countries (eligible for GAVI Alliance funding). Belgium Nov 2006 (Rotarix(TM)); June 2007 (RotaTeq®) ~90% (at least one dose) Marked delayed and attenuated peak of RV activity; >80% (95%CI: 78.7-81.4%) reduction in infections in children =3 years (too old to have been vaccinated) [28].Reduction (60-80%) in RV hospitalisations in children
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.12.002